CCM
DNLI icon

CAAS Capital Management’s Denali Therapeutics DNLI Stock Holding History

CAAS Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-232,796
Closed -$13.3M – 1097
2021
Q1 		$13.3M Buy
232,796
+52,333
+29% +$3.5M 0.14% 169
2020
Q4 		$15.1M Sell
180,463
-877,908
-83% -$53.1M 0.14% 144
2020
Q3 		$37.9M Sell
1,058,371
-498,537
-32% -$15M 0.88% 25
2020
Q2 		$37.6M Buy
1,556,908
+524,881
+51% +$12.3M 1.24% 23
2020
Q1 		$18.1M Buy
+1,032,027
New +$21.5M 1.89% 16

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAAS Capital Management's DNLI Position: Q2 2021 in Review

CAAS Capital Management sold out of Denali Therapeutics (DNLI) in Q2 2021, closing a stake of 232,796 shares — an estimated $13.3M sold.

CAAS Capital Management first reported a position in DNLI in Q1 2020 and held it in 5 quarters. The position peaked at $37.9M in Q3 2020. 210 funds tracked by Wall St. Rank hold DNLI as of Q2 2021.

  • CAAS Capital Management reported no remaining Denali Therapeutics position as of Q2 2021 after selling out during the quarter.
  • CAAS Capital Management sold 232,796 Denali Therapeutics shares in Q2 2021, an estimated $13.3M.
  • CAAS Capital Management first reported a position in Denali Therapeutics in Q1 2020 and held it in 5 quarters.
  • CAAS Capital Management's Denali Therapeutics position peaked at $37.9M in Q3 2020.
  • 210 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2021.

Based on CAAS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.